Loading…
← CockpitCompetitor Analysis › 301087.SZ Cofoe Medical Technology Co., Ltd. Class AOpen in the cockpit ↗

Cofoe Medical Technology Co., Ltd. Class A301087.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese maker of home medical devices — glucose meters, lancets and disposable diagnostic consumables.

≈ A Chinese home-diagnostics device makerMomentum leader 80
Mkt cap
$1.60B
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$16.6M
20-day average traded
Fwd P/E
25.1×
forward earnings
ROIC−WACC
+2.6 pp
WACC 9.1%
Hurdle
+4 pp
Req g minus delivered
Next earnings
167 days
4 May 2027
Close · CNYCN¥47.43
1D+1.9%
1W-2.0%
1M-9.6%
3M-5.1%
6M-6.0%
YTD+6.2%
1Y+9.6%
ATR %4.5%
52w lowhigh25.9% off high

What Cofoe Medical Technology does

Chinese maker of home medical devices — glucose meters, lancets and disposable diagnostic consumables.

Sells branded home-use devices largely through online shops and pharmacy chains, with marketing and sales channels a major cost. Disposable test strips used with its meters bring repeat purchases.

In one line: A Chinese home-diagnostics device maker.

Products and services

  • Blood glucose meters
  • Lancets/test strips
  • Rapid diagnostic test kits

Customers

  • Retail pharmacies
  • Consumers
  • Export distributors

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Home glucose monitoring & diagnostic…

What could go right

  • Home health monitoring/export demand

What could go wrong

  • Price competition in glucose-meter category

Moat: none (distribution). Competitive home-diagnostics category with several similar domestic makers.

Headquarters: Zhuhai, Guangdong, China · Employees: 5,081

Named competitors

Cofoe Medical Technology at a glance

Size Cofoe Medical Technology (301087.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.60B, the 1432nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥47.43 on 18 Nov 2026.

Performance Over six months the shares fell 6.0%, against +1.9% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 33.5% over the last twelve months (peer median +8.6%); the operating margin is 9.9% (peer median 10.6%).

Valuation It trades at 25.1× forward earnings against a peer median of 22.0× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.6 points above its cost of capital (9.1% WACC).

Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026Peer median 102301087.SZ 99
Six months, rebased to 100: Cofoe Medical Technology against the median of its 20 peers (local-currency closes).

Cofoe Medical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.18BCN¥3.37BCN¥2.98BCN¥2.84BCN¥2.97B
Revenue growth—+13%+5%-4%—
Gross profitCN¥2.37BCN¥1.65BCN¥1.42BCN¥1.12BCN¥1.09B
EBITDAn/aCN¥528MCN¥491MCN¥366MCN¥376M
Net incomeCN¥417MCN¥372MCN¥312MCN¥254MCN¥302M
Free cash flowCN¥259MCN¥557MCN¥557MCN¥64.2M-CN¥478M
Capital expenditureCN¥141MCN¥178MCN¥120MCN¥373MCN¥640M
Total debtCN¥1.33BCN¥917MCN¥1.00BCN¥744MCN¥577M

Quarterly statements and history in the cockpit →

Cofoe Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%6885316699BFLYVITRENOV68496880168086INSPKMTSXRAYEMBLA301363LMATELN300049300298PRCTCHEMM7716301087.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Cofoe Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×6885316699VITRENOV68496880168086INSPXRAYEMBLA301363LMATELN300049CHEMM7716301087.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cofoe Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6699VITRENOV6849688016INSPXRAYEMBLA301363LMATELN300049300298CHEMM301087.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Cofoe Medical Technology is the large dot.

Cofoe Medical Technology competitors and peer comparison

Head to head with its named competitors (301087.SZ vs 300298.SZ vs 002432.SZ vs 002223.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Cofoe Medical Technology 301087.SZ$1.60B-6%+33%10%25.1×11.2%
Sinocare 300298.SZ$1.45B+4%+7%6%21.5×9.5%
Andon Health 002432.SZ$3.86B-24%-30%-26%16.1×-6.6%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZ$4.18B-3%-1%13%20.0×4.9%

How Cofoe Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cofoe Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure301087.SZPeer medianRank in peer set
1-month return-9.6%-0.1%4th lowest of 21
6-month return-6.0%+1.9%10th lowest of 21
Distance from 52-week high-25.9%-25.6%11th highest of 21
Revenue growth (TTM)+33.5%+8.6%5th highest of 21
Operating margin9.9%10.6%11th highest of 21
Forward P/E25.1×22.0×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)11.2%10.7%8th most demanding of 16
Growth delivered (Del g)+7.4%+14.0%4th lowest of 16
Hurdle (Req g minus delivered)+3.8 pp-8.8 pp4th most demanding of 16
ROIC minus cost of capital+2.6 pp+2.3 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%

Questions

Who are Cofoe Medical Technology's main competitors?
Named competitors: Sinocare (300298.SZ), Andon Health (002432.SZ), Yuwell (Yuyue) (002223.SZ). The cockpit's measured peer set (industry) also includes Wuxi Unicomp Technology (688531.SS), Angelalign Technology (6699.HK), Butterfly Network (BFLY), Vitrolife (VITR.ST), Enovis (ENOV), Nihon Kohden (6849.T).
Is Cofoe Medical Technology expensive compared with its peers?
On forward p/e it trades at 25.1× against a peer median of 22.0×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Cofoe Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -6.0% against +1.9% for the median peer; over one year +9.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.